Lantheus (NASDAQ:LNTH) Hits New 12-Month High – Time to Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $104.50 and last traded at $104.32, with a volume of 1223938 shares trading hands. The stock had previously closed at $100.24.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citizens Jmp increased their target price on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Truist Financial reiterated a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Finally, William Blair reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Up 4.1%

The firm has a 50 day moving average of $89.53 and a 200 day moving average of $76.10. The firm has a market cap of $6.79 billion, a price-to-earnings ratio of 25.14 and a beta of -0.03. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter last year, the firm posted $1.53 earnings per share. The firm’s revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds have recently added to or reduced their stakes in the company. Abel Hall LLC grew its stake in Lantheus by 4.6% in the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after acquiring an additional 172 shares during the period. Smartleaf Asset Management LLC grew its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. grew its stake in Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 230 shares during the period. Vident Advisory LLC grew its stake in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after acquiring an additional 230 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 275 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.